Fluidigm Announces Second Quarter 2018 Financial Results

South San Francisco, California, UNITED STATES

Total revenue increases 11 percent to $26.4 million

Mass cytometry revenue growth of 32 percent

Total consumables revenue growth of 19 percent

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter ended June 30, 2018.

Second Quarter Highlights

  • Total revenue increased 11 percent to $26.4 million from $23.9 million in the second quarter of 2017, with mass cytometry revenue growth of 32 percent and total consumables revenue growth of 19 percent compared to the year ago period.
  • GAAP net loss was $16.2 million, compared with a GAAP net loss of $16.9 million for the second quarter of 2017.
  • Non-GAAP net loss was $6.8 million, compared with a $9.0 million non-GAAP net loss for the second quarter of 2017.

“We’re pleased with our strong performance this quarter, with exceptional top-line revenue growth in mass cytometry and total consumables,” said Chris Linthwaite, President and CEO. “We delivered disciplined operating expense and cash management.”

“This quarter, we surpassed a key milestone with fifty percent penetration at US Comprehensive Cancer Centers. Demonstrating sustained momentum for mass cytometry market expansion, we also saw strategic placements in Asia-Pacific and Europe and an exciting placement at a CAR T cell industry leader,” added Linthwaite.We are focused on delivering more growth and product innovation in the second half of 2018. Across all technology platforms we are experiencing demand driven by questions related to immune function.”

A full reconciliation of GAAP to non-GAAP measures can be found in the tables of this news release.

Second Quarter 2018 Results

Revenue by category:

  • Instrument revenue increased 5 percent to $10.4 million from $9.9 million in the year ago period. Higher revenue from mass cytometry instruments was partially offset by lower revenue from genomics instruments.
  • Consumables revenue increased 19 percent to $11.4 million from $9.6 million in the year ago period, with growth in both mass cytometry reagents and high-throughput genomics products, partially offset by decreased revenue from single-cell genomics products.
  • Service revenue increased 8 percent to $4.7 million from $4.3 million in the year ago period, with growth in service for mass cytometry systems, partially offset by a decrease in service for genomics systems.

Revenue by market:

  • Genomics revenue, comprising instruments, consumables, and service, decreased 5 percent to $12.8 million from $13.5 million in the prior year period. Genomics product revenue decreased 3 percent to $10.5 million from $10.9 million in the prior year period, mainly due to lower high-throughput genomics instrument sales and single-cell genomics product sales, partially offset by an increase in high-throughput genomics consumable products.
  • Mass cytometry revenue, comprising instruments, consumables, and service, increased 32 percent to $13.7 million from $10.4 million in the prior year period. Mass cytometry product revenue increased 31 percent to $11.3 million from $8.6 million in the prior year.

Total revenue by geographic area:

Geographic AreaRevenue by GeographyYear-over-Year Change% of Total Revenue
United States$12.0 million3%46%
Europe$9.1 million18%34%
Asia-Pacific$4.8 million24%18%
Other$0.5 million(23%)2%

Product margin:

GAAP product margin was 48.8 percent in the second quarter of 2018 compared to ­­­44.6 percent in the year ago period and 50.1 percent the first quarter. Non-GAAP product margin was 65.0 percent in the second quarter of 2018 compared to 63.0 percent in the year ago period and 67.2 percent in the first quarter. The increase in year-over-year product margins was primarily due to product mix and average selling prices, partially offset by higher costs from lower production volumes. The increase in GAAP product margin was also due to fixed amortization over higher revenue in the second quarter of 2018. The sequential decline in product margins was primarily due to product mix.

Cash, cash equivalents, and investments as of June 30, 2018:

Cash, cash equivalents, and investments as of June 30, 2018, were $40.4 million. Cash, cash equivalents, and investments as of March 31, 2018, were $47.3 million.

Operational and Business Progress

New product innovations:

  • Lower-Cost, Full-Length mRNA Sequencing Application for the C1™: In July, Fluidigm launched a new workflow application that the company developed with New England Biolabs for full-length mRNA sequencing analysis. This application is ideal for validation and further interrogation of new single-cell populations identified by ultrahigh throughput methods, expanding the capability of the C1 to advance new single-cell discoveries.
  • First Multimodal Single-Cell Application for the C1: In July, Fluidigm announced a new T-ATAC-seq application for use on the C system. Using the C1 Open App™ application, Stanford University researchers led by Dr. Ansuman Satpathy developed T-ATAC-seq to pair specific receptor sequences and epigenomic states in single cells. This application provides a powerful tool to uncover new insights into the development of the immune system and its role in a range of human disease. The research is published in Nature Medicine, and the application is publicly available on Fluidigm® Script Hub.
  • Advanta Sample Identification Genotyping Panel for Translational and Clinical Research: In June, Fluidigm launched the Advanta Sample ID Genotyping Panel for the Biomark™ HD system. This panel enables laboratories to accurately detect a unique genetic fingerprint from each sample at each stage of the sample journey. By utilizing the Biomark HD system, the workflow offers many additional benefits to sample identification, including decreased hands-on time and significant cost savings compared to traditional qPCR methods.

Strategic agreements:

  • Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service: In June, Fluidigm announced a co-marketing agreement with Genomenon to offer evidence-based panel design services for translational and clinical disease research. Through this joint panel design services offering, researchers will be able to accelerate the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels for use with highly efficient Fluidigm automated microfluidic systems.

Third Quarter 2018 Guidance  

  • Total revenue of $­­­­­­26 million to $29 million.
  • GAAP operating expenses of $27.5 million to $28.5 million.
  • Non-GAAP operating expenses of $24.5 million to $25.5 million excluding stock-based compensation and depreciation and amortization expenses of approximately $2 million and $1 million, respectively. 
  • Total cash outflow of $7.5 million to $8.5 million.

Conference Call Information

Fluidigm will host a conference call today, August 2, 2018, at 2:00 p.m. PT (5:00 p.m. ET) to discuss second quarter 2018 financial results and operational progress. Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 9766389. A live webcast of the conference call will be available online from the Investor Relations page of the Company’s website at http://investors.fluidigm.com/events.cfm.

The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on August 2, 2018.

After the live webcast, the call will be archived on Fluidigm’s Investor Relations page at http://investors.fluidigm.com/. In addition, a telephone replay of the teleconference will be available 90 minutes after the end of the call. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number: 9766389. The telephone replay will be available until August 9.

Statement Regarding Use of Non-GAAP Financial Information

Fluidigm has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods ended June 30, 2018, and June 30, 2017, as well as projected for the third quarter of 2018. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Our estimates of forward-looking non-GAAP operating expenses exclude estimates for stock-based compensation expense and depreciation and amortization; loss on disposal of property and equipment; future changes relating to developed and acquired technologies; other intangible assets; and income taxes, among other items, certain of which are presented in the tables accompanying our earnings release. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding growth in product sales, strategic plans, market growth in immunology and immuno-oncology, anticipated benefits for collaborations and new products, and projected revenues, expenses, and cash flows for the third quarter of 2018. Forward‑looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to reliance on sales of capital equipment for a significant proportion of revenues in each quarter; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; uncertainties in contractual relationships; Fluidigm research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in the Fluidigm Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including the Fluidigm Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm, the Fluidigm logo, Advanta, Biomark, C1, C1 Open App, and Script Hub are trademarks and/or registered trademarks of Fluidigm Corporation. All other trademarks are the sole property of their respective owners.


Agnes Lee
Vice President, Investor Relations
Fluidigm Corporation
650 416 7423

 (In thousands, except per share amounts) 
   Three Months Ended June 30, Six Months Ended June 30, 
    2018   2017   2018   2017  
    Instruments $  10,421  $  9,928  $  17,941  $  20,665  
    Consumables    11,356     9,572     24,313     20,142  
   Product revenue    21,777     19,500     42,254     40,807  
   Service revenue    4,651     4,319     9,422     8,486  
   License revenue    -     93     -     152  
 Total revenue   26,428     23,912     51,676     49,445  
 Costs and expenses:        
   Cost of product revenue    11,160     10,794     21,382     21,644  
   Cost of service revenue    1,680     1,169     3,278     2,288  
   Research and development    7,386     7,461     14,642     15,986  
   Selling, general and administrative    18,987     20,975     37,792     43,551  
 Total costs and expenses   39,213     40,399     77,094     83,469  
 Loss from operations   (12,785)    (16,487)    (25,418)    (34,024) 
 Interest expense   (3,916)    (1,456)    (5,805)    (2,911) 
 Other income, net    256     183     348     193  
 Loss before income taxes    (16,445)    (17,760)    (30,875)    (36,742) 
 Income tax benefit    204     827     1,387     2,608  
 Net loss$  (16,241) $  (16,933) $  (29,488) $  (34,134) 
 Net loss per share, basic and diluted$  (0.42) $  (0.58) $  (0.76) $  (1.17) 
 Shares used in computing net loss per share, basic and diluted  39,003   29,344   38,930   29,292  

(In thousands) 
     June 30, 2018 December 31, 2017 (1) 
Current assets:       
  Cash and cash equivalents   $  39,424 $  58,056 
  Short-term investments      996    5,080 
  Accounts receivable, net      16,874    15,049 
  Inventories      15,251    15,088 
  Prepaid expenses and other current assets      2,702    1,528 
Total current assets      75,247    94,801 
Property and equipment, net       10,424    12,301 
Other non-current assets      6,324    7,541 
Developed technology, net      63,000    68,600 
Goodwill       104,108    104,108 
Total assets   $  259,103 $  287,351 
Current liabilities:       
  Accounts payable   $  6,642 $  4,211 
  Accrued compensation and related benefits      11,880    10,535 
  Other accrued liabilities      7,372    8,490 
  Deferred revenue, current portion      10,756    10,238 
Total current liabilities      36,650    33,474 
Convertible notes, net      166,758    195,238 
Deferred tax liability, net      14,068    16,919 
Other non-current liabilities      6,794    10,785 
Total liabilities      224,270    256,416 
Total stockholders' equity      34,833    30,935 
Total liabilities and stockholders' equity  $  259,103 $  287,351 
(1) Derived from audited consolidated financial statements  

(In thousands) 
      Six Months Ended June 30, 
       2018   2017  
Operating activities    
Net loss   $  (29,488) $  (34,134) 
Depreciation and amortization   6,015     4,088  
Stock-based compensation expense   3,754     4,775  
Amortization of developed technology   5,600     5,600  
Other non-cash items   (41)    (417) 
Changes in assets and liabilities, net   (6,339)    3,310  
Net cash used in operating activities   (20,499)    (16,778) 
Investing activities    
Purchases of investments   (1,451)    (1,452) 
Proceeds from sales and maturities of investments   5,541     23,375  
Purchases of property and equipment   (154)    (834) 
Net cash (used in) provided by investing activities   3,936     21,089  
Financing activities    
Payment of debt issuance costs   (2,638)    -  
Proceeds from issuance of common stock through stock plans, net of tax   562     (46) 
Proceeds from exercise of stock options   24     -  
Payments for taxes related to net share settlement of equity awards   (100)    -  
Net cash (used in) provided by financing activities   (2,152)    (46) 
Effect of foreign exchange rate fluctuations on cash and cash equivalents   83     287  
Net (decrease) increase in cash and cash equivalents   (18,632)    4,552  
Cash and cash equivalents at beginning of period   58,056     35,045  
Cash and cash equivalents at end of period$  39,424  $  39,597  

(In thousands, except per share amounts) 
   Three Months Ended June 30,  Six Months Ended June 30,  
     2018   2017   2018   2017  
Net loss (GAAP)   $  (16,241) $  (16,933) $  (29,488) $  (34,134) 
Stock-based compensation expense     2,007     2,329     3,754     4,775  
Amortization of developed technology  (a)    2,800     2,800     5,600     5,600  
Interest expense (b)      3,916     1,456     5,805     2,911  
Depreciation and amortization      1,409     2,048     2,842     3,919  
Benefit from acquisition related income taxes (c)     (711)    (655)    (1,627)    (1,658) 
Net loss (Non-GAAP)   $  (6,820) $  (8,955) $  (13,114) $  (18,587) 
Shares used in net loss per share calculation -          
basic and diluted (GAAP and Non-GAAP)    39,003     29,344     38,930     29,292  
Net loss per share - basic and diluted (GAAP) $  (0.42) $  (0.58) $  (0.76) $  (1.17) 
Net loss per share - basic and diluted (Non-GAAP) $  (0.17) $  (0.31) $  (0.34) $  (0.63) 
    Three Months Ended June 30,  Six Months Ended June 30,  
     2018   2017   2018   2017  
Product margin (GAAP)   $  10,617  $  8,706  $  20,872  $  19,163  
Amortization of developed technology  (a)    2,800     2,800     5,600     5,600  
Depreciation and amortization (d)      509     543     1,019     1,094  
Stock-based compensation expense (d)    221     229     425     569  
Product margin (Non-GAAP)   $  14,147  $  12,278  $  27,916  $  26,426  
Product margin percentage (GAAP)   48.8%  44.6%  49.4%  47.0% 
Product margin percentage (Non-GAAP)  65.0%  63.0%  66.1%  64.8% 
    Three Months Ended June 30,  Six Months Ended June 30,  
     2018   2017   2018   2017  
Operating expenses (GAAP)   $  26,373  $  28,436  $  52,434  $  59,537  
Stock-based compensation expense (e)    (1,786)    (2,100)    (3,329)    (4,206) 
Depreciation and amortization (e)     (900)    (1,505)    (1,823)    (2,825) 
Operating expenses (Non-GAAP)  $  23,687  $  24,831  $  47,282  $  52,506  
    Three Months Ended June 30,  Six Months Ended June 30,  
     2018   2017   2018   2017  
Loss from operations (GAAP)   $  (12,785) $  (16,487) $  (25,418) $  (34,024) 
Stock-based compensation expense      2,007     2,329     3,754     4,775  
Amortization of developed technology  (a)    2,800     2,800     5,600     5,600  
Depreciation and amortization (e)     1,409     2,048     2,842     3,919  
Loss from operations (Non-GAAP)  $  (6,569) $  (9,310) $  (13,222) $  (19,730) 
(a) represents amortization of developed technology in connection with the DVS acquisition      
(b) represents interest expense on Senior Convertible Notes       
(c) represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition     
(d) represents expense associated with cost of product revenue        
(e) represents expense associated with research and development, selling, general and administrative activities